Corcept Therapeutics Incorporated is a commercial-stage biotechnology company focused on the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol activity. The company markets Korlym (mifepristone) in the United States for the treatment of hypercortisolism, also known as Cushing’s syndrome, and has made an authorized generic version available. Its pipeline includes relacorilant, a selective cortisol modulator being developed for hypercortisolism, as well as lead compounds under evaluation for solid tumors, amyotrophic lateral sclerosis (ALS), and metabolic dysfunction-associated steatohepatitis (MASH). The company operates in the United States, utilizing sales representatives and medical science liaisons to reach physicians. It has utilized specialty pharmacy partners, including Optime Care and Curant Health Georgia, to distribute its products and provide logistical support. Corcept conducts clinical trials such as CATALYST and MOMENTUM to evaluate the prevalence and treatment of hypercortisolism in patients with diabetes and resistant hypertension. The company has discovered over 1,000 proprietary cortisol modulators that bind to the glucocorticoid receptor without affinity for the progesterone receptor.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage corcept.com
Sector Healthcare IR page ir.corcept.com
Tags
cortisol modulation, endocrinology, oncology, metabolic disorders, neurology, cushing's syndrome, mash, als, glucocorticoid receptor, selective cortisol modulators, Korlym, mifepristone, relacorilant, Optime Care, Curant Health Georgia, CATALYST, MOMENTUM, GRACE, GRADIENT
Press page —

Metrics

Valuation  
Market cap $ 7.999B
Market cap (USD) $ 7.999B
P/E 57.55
PEG —
P/BV 9.59
P/S 8.30
P/OCF 40.38
P/FCF 41.10
Dividend yield —
Turnover / mcap —
Returns  
ROE 15.0%
ROI 18.7%
ROIC 8.4%
Profit margin 13.1%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) -1.0%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 76
Quality score 11.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004
Revenue 761.407M 675.04M 482.375M 401.858M 365.978M 353.874M 306.486M 251.247M 159.201M 81.321M 50.286M 26.551M 10.357M 3.307M — — — — — — — —
Net profit 99.652M 141.209M 106.14M 101.418M 112.512M 106.011M 94.181M 75.41M 129.122M 8.14M -6.408M -31.383M -46.011M -38.048M -32.354M -25.966M — — — — — —
Free cash flow 141.785M 195.895M 126.9M 119.91M 167.423M 150.732M 135.029M 115.367M 60.516M 18.197M 3.113M -27.55M -37.185M -36.171M -27.425M — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004
Share price 34.8 50.39 32.48 20.31 19.8 26.16 12.1 13.36 18.06 7.26 4.98 3 3.21 1.42 3.45 3.82 1.41 2.77 3.07 1 4.17 —
Price performance 12m -0.31 0.55 0.6 0.03 -0.24 1.16 -0.09 -0.26 1.49 0.46 0.66 -0.07 1.27 -0.59 -0.1 1.72 -0.49 -0.1 2.07 -0.76 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 9.86M 15.3M 17.6M 19.9M 26.2M 27.6M 31.1M 41.1M 54M 59.8M
↳ YoY growth +58.5% +55.2% +15.0% +13.3% +31.5% +5.4% +12.4% +32.4% +31.3% +10.8%
↳ 5y CAGR +94.0% +65.2% +43.0% +33.3% +22.9% +15.2% +18.5% +22.1% +17.9%
Borrowings, current (USD) 14.7M 0.00 — — — — — — — —
Borrowings, non-current (USD) 0.00 0.00 — — — — — — — —
Lease liabilities (USD) — — — 3.46M 2.55M 526,000 1.14M 151,000 6.94M 6.11M
Cash and deposits (USD) 51.5M 31.1M 41.6M 31.3M 76.2M 77.6M 66.3M 136M 128M 120M
Right-of-use assets (USD) — — — 3.45M 2.51M 514,000 1.14M 120,000 5.32M 4.58M
Net debt (borrowings + leases - cash) (USD) -36.9M -31.1M — — — — — — — —
Cash flow detail
Operating cash flow (USD) 18.4M 60.9M 116M 136M 152M 168M 120M 127M 198M 142M
Purchases of property, plant and equipment (USD) -194,000 -419,000 -298,000 -1.09M -1.24M -469,000 -413,000 -139,000 -2.17M -211,000
Change in receivables (cash effect) (USD) -3.64M -5.44M -2.29M -2.34M -6.27M -1.43M -3.43M -10.1M -12.9M -5.81M
Change in inventories (cash effect) (USD) -682,000 -2.26M -7.78M -1.04M -3.51M 3.44M 1.2M 1.27M 305,000 -7.48M
Change in payables (cash effect) (USD) 965,000 6.29M -389,000 -735,000 3.16M -3.6M 4.76M 5.78M -2.25M 25.1M
Share buybacks (cash effect) (USD) 0.00 0.00 -23.7M -31M -9.95M — 0.00 0.00 -15.7M -173M
Income taxes paid (cash effect) (USD) -40,000 -377,000 -1.35M -6.74M -10.9M -9.1M -39.7M -47.6M -60.3M -13M
Share-based compensation (USD) 7.06M 13.4M 23.7M 29.3M 33.5M 42.9M 42.4M 48.9M 61.4M 84.5M
Operating cash flow before change in receivables (USD) 22M 66.4M 118M 138M 158M 169M 124M 137M 211M 148M
Free cash flow (OCF - PPE - intangibles) (USD) 18.2M 60.5M 115M 135M 151M 167M 120M 127M 196M 142M
Income detail
Research and development expense (USD) 23.8M 40.4M 75.2M 89M 115M 114M 131M 184M 247M 255M
↳ 5y CAGR +2.6% +23.5% +29.7% +37.1% +49.4% +36.7% +26.5% +19.6% +22.6% +17.3%
Total comprehensive income (USD) 8.14M 129M 75.4M 94.5M 106M 112M 101M 108M 140M 102M
Comprehensive income to owners (USD) 8.14M 129M 75.4M 94.5M 106M 112M 101M 108M 140M 102M
Provision for credit losses (USD) 11.2M 20.7M 31.3M 25.2M 28.2M — — — — —
Credit cost ratio (credit losses / average receivables) (%) 138.9% 164.8% 190.4% 134.1% 122.3% — — — — —
Reported Feb 26, 2019 Feb 26, 2019 Feb 23, 2021 Feb 15, 2022 Feb 28, 2023 Feb 15, 2022 Feb 26, 2025 Feb 26, 2025 Feb 26, 2025 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 3, 2026 at 4:05 PM EST

  • Revenue of $340.5 million, a 64 percent increase over the same period in 2025

  • Korlym® and authorized generic product revenue of $249.1 million

  • Lifyorli® product revenue of $91.4 million

  • Reiterated 2026 revenue guidance of $1.1 – $1.2 billion

  • Net income of $126.8 million, compared to $19.7 million in third quarter 2025

  • Net income per common share (diluted) of $1.01, compared to $0.16 in third quarter 2025

  • Quarterly cash and investments increase of $117.7 million, to $662.3 million

  • BELLA Part A trial results in platinum-resistant ovarian cancer: Patients who received Lifyorli (relacorilant) in addition to nab-paclitaxel and bevacizumab demonstrated clinically meaningful progression-free survival (PFS), objective response rate (ORR) and overall survival (OS), with the most pronounced results being in patients earliest in their course of treatment in the platinum-resistant setting, including patients who had no prior treatment with bevacizumab

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 3, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the third quarter.

Financial Results

“Awareness of the importance of diagnosing and treating patients with Cushing’s syndrome is steadily increasing and is driving the growth of our endocrinology business,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer. “Lifyorli’s uptake in ovarian cancer has been both very rapid and broad. Since its April 1st launch, more than 2,300 patients have received the medication. More than 1,700 physicians have prescribed it. We expect continued growth in both businesses and have reiterated our 2026 revenue guidance of $1.1 – $1.2 billion.”

Corcept’s third quarter 2026 revenue was $340.5 million, compared to $256.1 million in the second quarter of 2026. Korlym and authorized generic revenue increased 19 percent, to $249.1 million. Lifyorli revenue grew 92 percent, to $91.4 million.

Third quarter 2026 operating expenses were $225.7 million, compared to $214.8 million in the second quarter of 2026. Third quarter 2026 net income was $126.8 million, compared to $43.0 million in the second quarter of 2026.

Cash and investments were $662.3 million at September 30, 2026, compared to $544.6 million at June 30, 2026. The balance at September 30, 2026 reflects the acquisition of $43.7 million of common stock in the third quarter pursuant to the company’s stock repurchase program as well as shares acquired upon the exercise of employee stock options and the vesting of restricted stock grants.

Clinical Development

Hypercortisolism (Cushing’s Syndrome)

  • American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD)’s Consensus Report on the Management of Type 2 Diabetes, published in October 2026, recommends screening for hypercortisolism in diabetic patients with poor glucose control despite ongoing medications; cites mifepristone as a potentially beneficial treatment

  • Relacorilant for patients with Cushing’s syndrome – Resubmitted New Drug Application Prescription Drug User Fee Act (PDUFA) date of December 17, 2026

“The ADA and EASD consensus statement is an important advance for the many patients whose difficult-to-control hyperglycemia is a manifestation of undiagnosed Cushing’s syndrome,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. “Optimal care starts with screening and a correct diagnosis. The ADA/EASD report also identifies mifepristone as a potential treatment, citing the positive results of our CATALYST trial.”

Oncology

Relacorilant in Combination with Chemotherapy

  • BELLA Part A – Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab in 95 patients with platinum-resistant ovarian cancer demonstrated clinically meaningful median PFS of 7.2 months, ORR of 59 percent and OS of 88 percent at 6-months (median OS not yet reached at the time of the primary analysis); benefit was most pronounced among patients who had not received bevacizumab previously (these patients had received fewer prior lines of treatment): median PFS of 8.1 months, ORR of 66 percent and 6-month OS of 91 percent; safety profile of relacorilant plus nab-paclitaxel and bevacizumab was consistent with the known profiles of each individual agent, with no new safety signals identified

  • BELLA Part B – Enrollment nearing completion in Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab in 90 patients with platinum-sensitive ovarian cancer whose disease progressed while on a PARP inhibitor – Results expected by the end of next year

  • BELLA Part C – Enrollment completed in Phase 2 trial of relacorilant plus nab-paclitaxel in 92 patients with endometrial cancer (received one or two prior lines of therapy) – Results expected by the end of next year

  • TRIDENT – Enrollment continues in Phase 2 trial of relacorilant plus nab-paclitaxel and gemcitabine as first-line therapy in 60 patients with pancreatic cancer – Results expected by the end of next year

  • STELLA – Initiated Phase 2 trial of relacorilant plus nab-paclitaxel in 50 patients with cervical cancer (received one or two prior lines of therapy), conducted in collaboration with ARCAGY-GINECO

  • Marketing Authorization Application (MAA) – European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended in September 2026 that the European Commission should approve our MAA for relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer – Approval expected by the end of this year

Relacorilant in Combination with Androgen Deprivation Therapy

  • Prostate cancer – Enrollment continues in randomized, placebo-controlled Phase 2 trial of relacorilant plus enzalutamide in early-stage prostate cancer, conducted in collaboration with the University of Chicago – Results expected by the end of next year

Nenocorilant in Combination with Immunotherapy

  • SYNERGY – Enrollment continues in Phase 1b dose-finding trial of nenocorilant plus nivolumab in 30 patients with a variety of solid tumors – Results expected by the end of next year

“Substantial preclinical and clinical data suggest that our proprietary, selective glucocorticoid receptor (GR) antagonists benefit patients both by sensitizing their tumors to chemotherapy and by bolstering their immune system’s ability to combat the disease,” said Dr. Guyer. “Our goal is to establish GR antagonism as a mechanism for treating a broad range of solid tumors, in combination with a variety of anticancer therapies, at every stage of disease. Our BELLA Part A results provide the latest evidence of GR antagonism’s versatility, especially when administered earlier in the course of disease. Our current trials – BELLA (Parts B and C), TRIDENT and SYNERGY – will generate important data in 2027. But these studies are just the start. We are aggressively expanding our research activities, with the goal of helping many more patients.”

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  • MONARCH Study Design – Cohort A enrolled 82 patients with biopsy-confirmed MASH, randomized 2:1 to receive either 100 mg of miricorilant twice weekly or placebo for 48 weeks; Cohort B enrolled 93 patients with presumed MASH, randomized 2:1 to receive either (i) 100 mg of miricorilant twice weekly for 6 weeks, then 200 mg of miricorilant twice weekly for 18 weeks or (ii) placebo for 24 weeks

  • MONARCH Results – Patients who received 200 mg of miricorilant twice weekly experienced a significantly larger reduction in liver fat than patients who received 100 mg of miricorilant twice weekly; patients – in Cohort A – who received pre- and post-treatment liver biopsies experienced an improvement in fibrosis of 19 percent at 48 weeks; importantly, miricorilant was very well tolerated in both cohorts; the rate of adverse events between the miricorilant and placebo arms was virtually indistinguishable; we are starting a Phase 2 trial soon to evaluate a higher dose of miricorilant, 100 mg daily

“We are encouraged by the dose-dependent reductions in liver fat, and improvement in fibrosis observed at the very low doses of miricorilant administered in MONARCH. We plan to study higher doses, to see if miricorilant’s fat- and fibrosis-reducing activity can be realized without sacrificing its excellent tolerability,” said Dr. Guyer.

Amyotrophic Lateral Sclerosis (ALS)

  • DAZALS – Exploratory analyses showed that patients who received dazucorilant 300 mg exhibited an 84 percent reduction in risk of death during the study’s first year compared to patients who received placebo (hazard ratio: 0.16, p-value: 0.0009) – This benefit persisted into the study’s second year with an 87 percent reduction in risk of death (hazard ratio: 0.13, p-value: < 0.0001)

  • Phase 3 trial – Planned to begin next year

“In our Phase 2 DAZALS study, treatment with a cortisol modulator was associated with a profound reduction in early mortality, during a period when many patients with ALS still retain significant function and maintain good quality of life,” said Dr. Guyer. “We plan to begin a Phase 3 study next year.”

Conference Call

We will hold a conference call on November 3, 2026, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. A listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com.

About Corcept Therapeutics

For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders. We have discovered more than 1,000 proprietary selective glucocorticoid receptor antagonists. Our development activities include advanced clinical trials in patients with hypercortisolism, a variety of solid tumors, ALS and liver disease. In 2012, we introduced Korlym, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous Cushing’s syndrome. In March 2026, we introduced Lifyorli® as a treatment for patients with platinum-resistant ovarian cancer. Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist. We are headquartered in Redwood City, California. For more information, visit Corcept.com.

Forward-Looking Statements

Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations and are subject to risks and uncertainties that might cause our actual results to differ materially from any future results expressed or implied by such forward-looking statements.

In this press release, forward-looking statements include those concerning: our 2026 revenue guidance; our expectations for continued growth in both our endocrinology and our oncology business; resubmission of our NDA for relacorilant for the treatment of patients with Cushing’s syndrome and our expectation that the FDA will issue a decision on this NDA by December 17, 2026; our anticipation that the European Commission will approve our MAA for relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer by the end of this year; the potential for glucocorticoid receptor antagonism to be a mechanism for treating a broad range of cancer types and solid tumors in combination with a variety of anticancer therapies at every stage of disease; our ongoing and planned clinical trials and our plans to further expand our research activities with the goal of helping many more patients, including the expected enrollment of patients in our clinical trials, and the timing and outcome of the results of these trials; our expectation that certain of our current trials – BELLA (Parts B and C), TRIDENT and SYNERGY – will generate important data in 2027; our plan to study higher doses of miricorilant to determine if its fat- and fibrosis-reducing activity can be realized without sacrificing its tolerability; and our plan to begin a Phase 3 study of a cortisol modulator in the treatment of patients with ALS next year.

A further description of risks and uncertainties affecting our forward-looking statements can be found in our SEC filings, which are available at our website and the SEC’s website. These risks and uncertainties include, but are not limited to, those related to: our ability to operate our business; our efforts to study and develop Korlym, Lifyorli, relacorilant, miricorilant, dazucorilant, nenocorilant and our other product candidates; those molecules’ clinical attributes; regulatory approvals, mandates, oversight and other requirements imposed on our products or our business by laws, regulations or discretion of government authorities; and the scope and protective power of our intellectual property. We disclaim any intention or duty to update forward-looking statements made in this press release.

| | | | |

| CORCEPT THERAPEUTICS INCORPORATED CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) |

| | | | |

| | September 30, 2026 | | December 31, 2025(1) |

| | (Unaudited) | | |

| Assets | | | |

| Cash and investments | $ | 662,307 | | $ | 532,422 |

| Trade receivables, net of allowances | | 111,061 | | | 59,786 |

| Inventory | | 37,569 | | | 23,962 |

| Operating lease right-of-use asset | | 6,517 | | | 4,583 |

| Deferred tax assets, net | | 169,069 | | | 168,197 |

| Other assets | | 47,504 | | | 47,701 |

| Total assets | $ | 1,034,027 | | $ | 836,651 |

| Liabilities and Stockholders’ Equity | | | |

| Accounts payable | $ | 21,924 | | $ | 40,444 |

| Operating lease liabilities | | 8,991 | | | 6,107 |

| Other liabilities | | 169,372 | | | 142,295 |

| Stockholders’ equity | | 833,740 | | | 647,805 |

| Total liabilities and stockholders’ equity | $ | 1,034,027 | | $ | 836,651 |

| | | | |

| (1) Derived from audited financial statements at that date |

| |

| CORCEPT THERAPEUTICS INCORPORATED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (In thousands, except per share data) |

| | | | |

| | Three Months Ended | | Nine Months Ended |

| | September 30, | | September 30, |

| | 2026 | | 2025 | | 2026 | | 2025 |

| Revenues | | | | | | | |

| Product revenue, net | $ | 340,472 | | $ | 207,638 | | $ | 761,522 | | $ | 559,282 |

| | | | | | | | |

| Operating expenses | | | | | | | |

| Cost of sales | | 4,608 | | | 4,596 | | | 11,552 | | | 10,432 |

| Research and development | | 56,709 | | | 68,846 | | | 176,864 | | | 190,052 |

| Selling, general and administrative | | 164,431 | | | 123,977 | | | 466,683 | | | 318,488 |

| Total operating expenses | | 225,748 | | | 197,419 | | | 655,099 | | | 518,972 |

| Income from operations | | 114,724 | | | 10,219 | | | 106,423 | | | 40,310 |

| Interest and other income | | 5,583 | | | 5,024 | | | 15,100 | | | 16,243 |

| Income before income taxes | | 120,307 | | | 15,243 | | | 121,523 | | | 56,553 |

| Income tax benefit | | 6,471 | | | 4,425 | | | 16,481 | | | 18,811 |

| Net income | $ | 126,778 | | $ | 19,668 | | $ | 138,004 | | $ | 75,364 |

| | | | | | | | |

| Net income attributable to common stockholders | $ | 124,489 | | $ | 19,359 | | $ | 135,459 | | $ | 74,267 |

| | | | | | | | |

| Basic net income per common share | $ | 1.17 | | $ | 0.19 | | $ | 1.28 | | $ | 0.71 |

| | | | | | | | |

| Diluted net income per common share | $ | 1.01 | | $ | 0.16 | | $ | 1.13 | | $ | 0.62 |

| | | | | | | | |

| Weighted-average shares outstanding used in computing net income per common share | | | | | | | |

| Basic | | 106,628 | | | 103,545 | | | 105,488 | | | 103,919 |

| Diluted | | 123,201 | | | 119,439 | | | 119,407 | | | 119,981 |

| | | | | | | | |

| CORCEPT THERAPEUTICS INCORPORATED PRODUCT REVENUE, NET BY PRODUCT (In thousands) |

| | | | |

| | Three Months Ended | | Nine Months Ended |

| | September 30, | | September 30, |

| | 2026 | | 2025 | | 2026 | | 2025 |

| Korlym and authorized generic | $ | 249,067 | | $ | 207,638 | | $ | 622,553 | | $ | 559,282 |

| Lifyorli | | 91,405 | | | — | | | 138,969 | | | — |

| Product revenue, net | $ | 340,472 | | $ | 207,638 | | $ | 761,522 | | $ | 559,282 |

View source version on businesswire.com: https://www.businesswire.com/news/home/20261103499437/en/

Investor inquiries: [email protected]

Media inquiries: [email protected] www.corcept.com

Source: Corcept Therapeutics Incorporated

Email Alerts Print Page RSS Feeds

© 2026 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Linkedln | Your Privacy Choices

Scroll to top

Corcept Logo

The Global Privacy Signal that you have set in your devices browser has been recognized.

  • Your Privacy Choices

  • Strictly Necessary Cookies

  • Functional Cookies

  • Performance Cookies

  • Targeting & Social Media Cookies

Your Privacy Choices

This website may use cookies as described in the categories on this page. By default, all cookie categories are "off" except Strictly Necessary Cookies which is "on." You may alter your cookie preferences for this website by using the "on/off" toggles and confirming your choices, or by using the buttons on the bottom of this page. Additional information about the company’s privacy practices can be found here Privacy Notice.

To exercise other rights as may be allowed by applicable privacy laws, please complete the form found here: Data Subject Request Form.

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you, which amount to a request for services, such as setting your privacy preferences, logging in or filling out forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not function. These cookies do not store any personally identifiable information.

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality. They may be set by us or by 3rd party providers whose services we have added to our pages. If you do not allow these cookies, then some or all of these services may not function properly.

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular, and see how visitors move around the site. We may collect your session ID, IP address, device identifiers, and your activity with the website. We may provide these cookies to 3rd party service providers to help us run these analytics. If you are located in Europe, the personal data may be sent to a country (eg United States) that has not been deemed to provide an adequate level of data protection or appropriate safeguards. By accepting these cookies, you consent to the data processing for analytics purposes and to the transfer of your personal data to the United States each time you visit our site. If you block or opt out of these cookies, we will not know when you have visited our site, and will not be able to monitor its performance.

Targeting & Social Media Cookies

Targeting & Social Media Cookies

  • Targeting Cookies

Switch Label

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant advertisements on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookie List

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Clear

checkbox label label

Apply Cancel

Reject All Cookies Allow All Cookies

Powered by Onetrust

October 27, 2026 at 4:05 PM EDT

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 27, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Conference Call Information

Participants must register in advance of the conference call by clicking here.Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller.

Additionally, a listen-only webcast will be available by clicking here.

A replay of the call will be available on the Investors / Events tab of Corcept.com.

October 26, 2026 at 8:00 AM EDT

  • Lifyorli (relacorilant) in combination with nab-paclitaxel and bevacizumab demonstrated clinically meaningful progression-free survival (PFS), objective response rate (ORR) and overall survival (OS), with the more pronounced results being in patients who had no prior treatment with bevacizumab.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 26, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced positive results from Part A of the company’s Phase 2 BELLA trial, which evaluated Lifyorli in combination with nab-paclitaxel and bevacizumab in 95 patients with platinum-resistant ovarian cancer.

In the study, patients treated with Lifyorli plus nab-paclitaxel and bevacizumab demonstrated a median PFS by investigator of 7.2 months compared to a median PFS of 5.4 months for Lifyorli plus nab-paclitaxel and 3.9 months for nab-paclitaxel alone in the pivotal Phase 3 ROSELLA study. ORR in BELLA was 59%, compared to 37% for Lifyorli plus nab-paclitaxel and 30% for nab-paclitaxel monotherapy in ROSELLA. Median OS had not been reached at the time of the primary analysis. In BELLA, 88% of patients were alive at the 6-month OS timepoint, compared to 82% for Lifyorli plus nab-paclitaxel and 77% for nab-paclitaxel alone in ROSELLA.

In BELLA, responses were more pronounced in patients who were bevacizumab-naive. Approximately half the patients enrolled in BELLA had not previously received bevacizumab. In these patients, median PFS was 8.1 months and ORR was 66%, with an OS at the 6-month mark of 91%.

The safety events were consistent with the known profiles of each individual agent in the combination and with Lifyorli combined with nab-paclitaxel, with no new safety signals identified. In BELLA Part A, the most common (≥25% of patients) adverse events were neutropenia, anemia, nausea, asthenia, nail disorder, peripheral neuropathy, fatigue, and leukopenia. Lifyorli is not approved for use in combination with bevacizumab. See full indication and important safety information below.

“Following ROSELLA’s outstanding results, these BELLA data provide valuable insight into adding bevacizumab to the Lifyorli/nab-paclitaxel treatment backbone,” said Domenica Lorusso, M.D., Ph.D., Director of the Gynaecological Oncology Unit at Humanitas Hospital San Pio X, Milan, and Full Professor of Obstetrics and Gynaecology, Humanitas University, Rozzano. “These findings help advance our understanding of both the efficacy and safety profile of this triplet combination as we work to expand treatment options for patients.”

Lifyorli is the first FDA-approved selective glucocorticoid receptor (GR) antagonist. In oncology, GR antagonism is a novel mechanism that counters cortisol-mediated immunosuppression and enhances chemotherapy sensitivity. Corcept expects that the findings from BELLA Part A will augment Lifyorli’s preferred status in the National Comprehensive Cancer Network**®** Clinical Practice Guidelines in Oncology (NCCN Guidelines) as a treatment for women with platinum-resistant ovarian cancer. Complete results from BELLA Part A will be presented at a medical conference next year.

BELLA Part A is a single-arm, open-label trial that enrolled 95 women with recurrent, platinum-resistant ovarian cancer at approximately 45 sites in North America, Europe and Asia-Pacific. Corcept is conducting clinical studies of its proprietary GR antagonists in platinum-sensitive ovarian, endometrial, cervical, pancreatic, prostate and other cancers in combination with various anti-cancer agents. Further information is available at Corcept.com/Pipeline-and-Clinical-Trials.

“Our goal is to demonstrate our proprietary selective GR antagonists’ ability to benefit patients with a wide array of solid tumors, in combination with many different anti-cancer agents,” said Bill Guyer, Pharm.D., Corcept’s Chief Development Officer. “These results provide more evidence of GR antagonism’s versatility – in this case, of Lifyroli’s potential to benefit patients when combined with nab-paclitaxel and bevacizumab, whether or not bevacizumab had been included in a patient’s prior treatment regimen. We look forward to presenting the full BELLA Part A data next year.”

About Ovarian Cancer

Ovarian cancer is the fifth most common cause of cancer death in women. Patients whose tumors return or resume growing less than six months after receiving platinum-containing therapy have "platinum-resistant" disease. There are few treatment options for these women. In the United States, approximately 20,000 women with platinum-resistant disease are candidates to start a new therapy each year. In Europe, the annual figure is the same or higher.

About Cortisol's Role in Oncology

Cortisol plays a role in tumor growth through several mechanisms. Cortisol suppresses the body's immune response, which weakens its ability to fight all diseases, including cancer. Cortisol also helps solid tumors resist chemotherapy by inhibiting apoptosis — the tumor-killing effect chemotherapy is meant to stimulate. In some cancers, cortisol promotes tumor growth by activating oncogenic signaling in the cells to which it binds.

Corcept is developing relacorilant in ovarian, endometrial, cervical, pancreatic and prostate cancers. Lifyorli (relacorilant) is proprietary to Corcept and is protected by composition of matter, method of use and other patents. It has been designated an orphan drug by the European Commission (EC) for the treatment of ovarian cancer. Corcept has received a positive opinion for its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for relacorilant to treat patients with platinum-resistant ovarian cancer.

About Lifyorli®

Lifyorli (relacorilant) is an oral medication taken the day before, the day of and the day after treatment with nab-paclitaxel in patients with platinum-resistant ovarian cancer. There is no biomarker requirement to receive Lifyorli. Lifyorli competitively binds to the glucocorticoid receptor (GR), where it mediates cortisol’s immunosuppressive effects and enhances chemotherapy sensitivity. Lifyorli does not have any effect at the body’s other steroid receptors. It the first U.S. Food and Drug Administration (FDA)-approved selective glucocorticoid receptor antagonist.

It is included in the National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a preferred regimen for patients with platinum-resistant ovarian cancer.

Corcept is committed to timely patient access for Lifyorli. For questions regarding product availability, please contact Lifyorli Support™ at 1-85-LIFYORLI (1-855-439-6754).

LIFYORLI Indication & Usage

LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens, at least one of which included bevacizumab.

IMPORTANT SAFETY INFORMATION

Contraindications:

LIFYORLI is contraindicated in patients receiving systemic glucocorticoids for lifesaving purposes (e.g., immunosuppression after organ transplantation) because LIFYORLI antagonizes the effect of glucocorticoids.

Warnings and Precautions:

Neutropenia and Severe Infections

LIFYORLI in combination with nab-paclitaxel can cause neutropenia, including febrile neutropenia and severe infections. There was one fatal event of septic shock with febrile neutropenia. Thirty-eight percent of patients initiated granulocyte colony-stimulating factor (G-CSF) during the first or second cycle of therapy.

Monitor complete blood counts prior to each weekly treatment with LIFYORLI in combination with nab-paclitaxel and as clinically indicated. Based on the severity of neutropenia, delay dose, reduce dose or permanently discontinue LIFYORLI in combination with nab-paclitaxel. Consider short-acting G-CSF administration as applicable. Consider the possibility of concurrent adrenal insufficiency, particularly in the setting of serious infection.

Adrenal Insufficiency

LIFYORLI is a reversible glucocorticoid receptor antagonist and can cause adrenal insufficiency. Adrenal insufficiency can occur at any time during treatment with LIFYORLI. The risk of adrenal insufficiency is increased in situations of stress, such as acute illness, infection, or surgery. Consider whether supplemental glucocorticoids are required in the perioperative period in patients who have received LIFYORLI within 30 days of surgery. Monitor patients receiving LIFYORLI for signs and symptoms of adrenal insufficiency. Withhold LIFYORLI and administer glucocorticoid therapy if adrenal insufficiency is suspected. High doses of supplemental glucocorticoids may be needed to overcome the glucocorticoid receptor antagonism produced by LIFYORLI. After resolution of adrenal insufficiency, resume previous dose, reduce dose or permanently discontinue LIFYORLI based on severity.

Exacerbation of Conditions Treated with Glucocorticoids

Use of LIFYORLI in patients taking systemic glucocorticoids for other conditions (e.g., autoimmune disorders) may exacerbate these conditions. LIFYORLI is a glucocorticoid receptor antagonist that may make systemic glucocorticoids less effective. Similarly, coadministration of systemic glucocorticoids may make LIFYORLI less effective. Monitor patients for reduced effectiveness of LIFYORLI and glucocorticoids in patients receiving both.

Embryo-Fetal Toxicity

LIFYORLI can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Verify pregnancy status of females of reproductive potential prior to initiating LIFYORLI treatment. Advise females of reproductive potential, including male patients with female partners of reproductive potential, to use effective contraception during treatment with LIFYORLI and for 1 week after the last dose.

Adverse Reactions:

Serious adverse reactions occurred in 35% of patients who received LIFYORLI in combination with nab-paclitaxel. Serious adverse reactions (≥2%) in patients were neutropenia (4%), pneumonia (3.2%), pleural effusion (3.2%), febrile neutropenia (2.1%), and fatigue (2.1%). Fatal adverse reactions (2.1%) in patients were septic shock (0.5%), cardiac arrest (0.5%), ischemic stroke (0.5%), and intestinal perforation (0.5%).

Permanent discontinuation of LIFYORLI in combination with nab-paclitaxel due to adverse reactions occurred in 9% of patients. The adverse reaction (>2%) that resulted in permanent discontinuation of LIFYORLI in patients was intestinal obstruction (2.6%). Dosage interruptions of LIFYORLI due to an adverse reaction occurred in 72% of patients. Adverse reactions (≥5%) that required dosage interruptions of LIFYORLI in combination with nab-paclitaxel in patients included neutropenia (44%), anemia (12%), and fatigue (7%). Adverse reactions requiring dose reductions of LIFYORLI included fatigue (1.6%), decreased appetite (1.2%), abdominal pain (0.5%), neutropenia (0.5%), edema (0.5%), and sciatica (0.5%). LIFYORLI should be interrupted or discontinued when nab-paclitaxel is interrupted or discontinued.

The most common adverse reactions (>20%) of patients treated with LIFYORLI plus nab-paclitaxel, including laboratory abnormalities, were decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.

Drug Interactions:

  • Strong CYP3A Inducers: Avoid coadministration of LIFYORLI plus nab-paclitaxel with strong CYP3A inducers. Both relacorilant and paclitaxel are CYP3A substrates. Coadministration of strong CYP3A inducers can decrease concentrations of relacorilant and paclitaxel, which may reduce their effectiveness.

  • CYP2C8 and Moderate CYP3A Inducers: Monitor for reduced effectiveness of LIFYORLI plus nab-paclitaxel with CYP2C8 inducers and moderate CYP3A inducers. Paclitaxel is a substrate of CYP2C8 and CYP3A, and relacorilant is a CYP3A substrate. Coadministration of CYP2C8 and moderate CYP3A inducers can decrease concentrations of paclitaxel and relacorilant, which may reduce their effectiveness.

  • CYP2C8 Inhibitors: Monitor for increased adverse reactions and modify the dosage for adverse reactions as recommended. Paclitaxel is a substrate of CYP2C8. Coadministration of CYP2C8 inhibitors may increase concentrations of paclitaxel, which may increase the risk of adverse reactions.

  • CYP3A Substrates: Avoid concomitant use unless otherwise recommended in the Prescribing Information for CYP3A substrates. Relacorilant is a strong CYP3A inhibitor. Relacorilant increases exposure of CYP3A substrates which may increase the risk for adverse reactions related to these substrates.

  • Certain CYP2C8 Substrates: Avoid concomitant use unless otherwise recommended in the Prescribing Information for CYP2C8 substrates where minimal concentration changes may lead to reduced effectiveness. Relacorilant is a weak CYP2C8 inducer. Relacorilant decreases exposure of CYP2C8 substrates which may decrease the effectiveness related to these substrates.

Use in Specific Populations:

  • Lactation: Advise women not to breastfeed during treatment with LIFYORLI and for 1 week after the last dose.

  • Geriatric Use: A higher incidence of grade 3-4 adverse events and dosage modification occurred in patients aged ≥65 years compared to younger adult patients.

  • Hepatic Impairment: Avoid LIFYORLI in combination with nab-paclitaxel in patients with moderate or severe hepatic impairment (total bilirubin >1.5 to 10x ULN and any AST).

Please see the full Prescribing Informationfor additional Important Safety Information.

About Corcept Therapeutics

For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders. We have discovered more than 1,000 proprietary selective glucocorticoid receptor antagonists. Our development activities include advanced clinical trials in patients with hypercortisolism, a variety of solid tumors, ALS and liver disease. In 2012, we introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous Cushing’s syndrome. In March 2026, we introduced Lifyorli® as a treatment for patients with platinum-resistant ovarian cancer. Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist. We are headquartered in Redwood City, California. For more information, visit Corcept.com.

Forward-Looking Statements

Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations and are subject to risks and uncertainties that might cause our actual results to differ materially from any future results expressed or implied by such forward-looking statements.

In this press release, forward-looking statements include those concerning: Lifyorli's efficacy, safety and other clinical attributes, including when administered in combination with nab-paclitaxel and bevacizumab; the ability of BELLA Part A to demonstrate a clinically meaningful overall survival benefit; our efforts to expand treatment options for patients with solid tumors and the outcome of such efforts; the ability of GR antagonism to meaningfully counter cortisol-mediated immunosuppression and enhance chemotherapy sensitivity; our plan to present the full results of BELLA Part A and the substance of those results; our ability to complete our ongoing and planned studies of GR antagonists in platinum-sensitive ovarian, endometrial, cervical, pancreatic, prostate and other cancers in combination with various anti-cancer agents and the results of those studies; and our ability to prove that GR antagonism can benefit patients with a wide array of solid tumors.

A further description of risks and uncertainties can be found in our SEC filings, which are available at our website and the SEC’s website. These risks and uncertainties include, but are not limited to, those related to our ability to: operate our business; study and develop Korlym, relacorilant, miricorilant, dazucorilant, nenocorilant and our other product candidates; those molecules’ clinical attributes, regulatory approvals, mandates, oversight and other requirements; and the scope and protective power of our intellectual property. We disclaim any intention or duty to update forward-looking statements made in this press release.

Prompts

Corcept Therapeutics Incorporated (ticker CORT), listed in United States.

ETFs Holding Corcept Therapeutics Incorporated

ETF Weight in ETF Shares Market value As of
LFSC 6.72% 74,897 $ 8.49M Aug 31, 2026
SPIT 5.39% 16,132 $ 1.829M Aug 31, 2026
FORH 3.45% 7,828 $ 680.645K Jun 30, 2026
ASCE 2.51% 33,940 $ 2.951M Jun 30, 2026
SURI 2.12% 20,568 $ 1.441M Nov 17, 2026
JSMD 1.06% 97,112 $ 11.118M Jul 31, 2026
FFF 0.22% 122 $ 14.058K Sep 30, 2026
REMC 0.19% 73 $ 6,347.35 Jun 30, 2026
SQLV 0.15% 500 $ 43.475K Jun 30, 2026
AFMC 0.15% 5,691 $ 393.931K Nov 16, 2026
AFSM 0.14% 2,936 $ 203.23K Nov 16, 2026
JMEE 0.13% 51,523 $ 3.61M Nov 17, 2026
SXQG 0.12% 994 $ 73.268K Nov 12, 2026
DFAS 0.10% 434,686 $ 32.041M Nov 12, 2026
VFMO 0.08% 12,800 $ 1.451M Aug 31, 2026
SMDX 0.07% 1,221 $ 84.518K Nov 17, 2026
MSSM 0.06% 3,882 $ 440.025K Aug 31, 2026
IALT short -0.05% -61,710 $ -4.272M Nov 16, 2026
AVIE 0.04% 103 $ 7,129.66 Nov 16, 2026
DCOR 0.01% 63,359 $ 4.67M Nov 12, 2026
AVSU 0.01% 661 $ 45.754K Nov 16, 2026
DFAU 0.01% 13,602 $ 1.003M Nov 12, 2026
DFAC 0.01% 84,025 $ 6.193M Nov 12, 2026
DFUS 0.00% 7,909 $ 582.972K Nov 12, 2026
DXUV 0.00% 80 $ 5,896.80 Nov 12, 2026
AVUS 0.00% 377 $ 26.096K Nov 16, 2026